



Plenary sitting

B8-0015/2017

4.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on lung cancer

Mireille D'Ornano

Motion for a European Parliament resolution on lung cancer

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas lung cancer affects 312 000 Europeans each year, causes 267 700 deaths annually in Europe and its treatment apparently costs the healthcare systems of the Member States USD 8.8 billion;
- B. whereas lung cancer is associated with a high mortality rate, as only 13% of those affected survive longer than five years after having contracted it, not least because of belated diagnosis in 70% of cases;
- C. whereas scientific progress concerning, in particular, non-small cell lung cancer, has apparently extended the prognosis of the individuals affected; whereas, in particular, a study carried out at the University of Göttingen (Germany) has demonstrated the efficacy of the drug tested (Atezolizumab) against PD-L1 molecules on the surface of cancer cells;
- D. whereas other studies would enable a vaccine against different types of lung cancer to be developed; whereas research into the human genome also constitutes scientific progress;
- 1. Encourages the Commission to support the search for innovative lung cancer treatments.